Ecnoglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes and obesity. This compound mimics the action of the naturally occurring GLP-1 hormone, promoting insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying, which collectively help to lower blood glucose levels. Ecnoglutide is characterized by its stability and prolonged action compared to native GLP-1, making it suitable for therapeutic use. Its pharmacokinetic profile typically includes a longer half-life, allowing for less frequent dosing. Additionally, it may exhibit a favorable side effect profile, with common adverse effects including gastrointestinal disturbances. As with other GLP-1 receptor agonists, it is essential to monitor for potential risks such as pancreatitis or thyroid tumors. Overall, Ecnoglutide represents a significant advancement in diabetes treatment, contributing to improved glycemic control and weight management in patients.

Ecnoglutide

2459531-73-6: Ecnoglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes and obesity. This compound mimics the action of the naturally occurring GLP-1 hormone, promoting insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying, which collectively help to lower blood glucose levels. Ecnoglutide is characterized by its stability and prolonged action compared to native GLP-1, making it suitable for therapeutic use. Its pharmacokinetic profile typically includes a longer half-life, allowing for less frequent dosing. Additionally, it may exhibit a favorable side effect profile, with common adverse effects including gastrointestinal disturbances. As with other GLP-1 receptor agonists, it is essential to monitor for potential risks such as pancreatitis or thyroid tumors. Overall, Ecnoglutide represents a significant advancement in diabetes treatment, contributing to improved glycemic control and weight management in patients.

<p>Ecnoglutide (XW003) is a glucagon-like peptide 1 (GLP-1) receptor agonist [1] .</p>

CAS 2459531-73-6

Ecnoglutide

Ecnoglutide

Ref: TM-T76234

Ecnoglutide

Ref: 4Z-PE-247001